Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Survey: Most Americans don't want injectable weight-loss drugs
Lots of people want to lose weight but they don't necessarily want to take regular injections to do it. That's the finding of a new national survey. It fou
WeightWatchers to offer compounded weight-loss drugs
WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.
Popular Weight Loss Drugs Now for Patients With Cancer?
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
Biotech Exec Warns That Weight-Loss Drugs Do "More Harm Than Good"
T here's always a new headline about weight-loss drugs, whether it's sharing new data on how many pounds someone has lost or a newly discovered side effect. Either way, there's no
How Much Do Weight Loss Drugs Cost with and without Insurance?
Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive,
3d
1 in 10 Americans have tried injectable weight loss medication—These are the cities with the most early adopters
Three cities in Hawaii, Minnesota, and Texas report the highest usage of injectable weight loss medications. Meanwhile, ...
3d
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
2d
Washingtonians share how they afford pricey weight loss medications
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
News Medical on MSN
4d
Survey: Most Americans skeptical about weight-loss injections
A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...
11d
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
5d
on MSN
Mounjaro will soon be available as a weight loss treatment on the NHS. Here's what that means for patients
The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback